Clinical Trial

Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

Name: Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation — clinical trial record (NCT07561554)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.

Trial Details

NCT Number	NCT07561554
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	Solid Tumors (Phase 1)
Enrollment	159 participants
Start Date	2026-03-06
Primary Completion	2028-12-02 (estimated)
Study Completion	2028-12-02 (estimated)
Updated on ClinicalTrials.gov	2026-05-01